Microbiota, not host origin drives ex vivo intestinal epithelial responses

Gut Microbes. 2022 Jan-Dec;14(1):2089003. doi: 10.1080/19490976.2022.2089003.

Abstract

Microbial dysbiosis is an established finding in patients with inflammatory bowel disease (IBD), but host-microbial interactions are poorly understood. We aimed to unravel the effect of microbiota exposure on intestinal epithelial cells. Confluent Transwell® organoid monolayers of eight UC patients and eight non-IBD controls were co-cultured for six hours with microbiota (3x108 cells) of UC patients or a healthy volunteer (HV), in the presence or absence of an inflammatory cytokine mix. Transepithelial electrical resistance (TEER), fluorescein isothiocyanate (FITC) dextran measurements, and RNA sequencing were performed on epithelial cells, and 16S rRNA sequencing on microbiota samples before and after co-culture. Transcriptomic response following microbiota exposure was not different between epithelial cells from UC patients or non-IBD controls. Following UC microbiota exposure, but not HV microbiota, a strong decrease in epithelial barrier integrity was observed in both UC and HV epithelial cells by TEER and FITC dextran measurements. Exposure of inflamed epithelium to UC microbiota induced transcriptomic stress pathways including activation of EGR1, MAPK and JAK/STAT signaling, as well as AP-1 family and FOSL transcripts. Stress responses after HV microbiota stimulation were milder. We conclude that not the epithelial cell origin (UC versus non-IBD) but the microbial donor drives transcriptomic responses, as exposure to UC microbiota was sufficient to induce stress responses in all epithelial cells. Further research on therapies to restore the microbial balance, to remove the constant trigger of dysbiosis, is required.

Keywords: Ulcerative colitis; dysbiosis; epithelial cells; microbiota; organoids.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Colitis, Ulcerative*
  • Dysbiosis / metabolism
  • Gastrointestinal Microbiome* / genetics
  • Humans
  • Inflammatory Bowel Diseases* / metabolism
  • Intestinal Mucosa / metabolism
  • Microbiota*
  • RNA, Ribosomal, 16S / genetics

Substances

  • RNA, Ribosomal, 16S

Grants and funding

This work was supported by the Research Foundation Flanders (FWO), Belgium by a PhD Fellowship strategic basic research (SB) grant (1S49419N) for K Arnauts, and a Strategic Basic Research (SBO) project (S003718N), by a CREA research grant of the KU Leuven (CREA/12/031), and a research grant by the European Crohn’s and Colitis Organisation (ZKC4621/10143459). K Arnauts received a research grant of the Belgian IBD Research and Development (BIRD) group, a doctoral scholarship of the KU Leuven and financial support of the Crohns and colitis ulcerosa vereniging - VZW. M Ferrante and J Sabino are Senior Clinical Investigators of the Research Foundation Flanders (FWO), Belgium. B Verstockt is supported by the Clinical Research Fund (KOOR), University Hospitals Belgium. P Sudhakar was supported by the European Research Council (ERC) by an ERC Advanced Grant (ERC-2015-AdG, 694679, CrUCCial).